AbbVie Inc

28 wrz 2026, 23:30 UTC

AbbVie Inc's stock is trading higher in after-market hours following FDA approval of JUVMO™ tablets, the first selective D1/D5 receptor agonist for Parkinson's disease.

25 wrz 2026, 23:51 UTC

AbbVie Inc received FDA approval for Juvmo (Tavapadon), a Parkinson's treatment, contributing to a modest rise in shares during after-market trading.

24 wrz 2026, 20:07 UTC

AbbVie Inc. shares fell slightly despite receiving Health Canada approval for EPKINLY in combination with lenalidomide and rituximab for treating follicular lymphoma.

23 wrz 2026, 23:01 UTC

AbbVie Inc. is down slightly in after-market trading, pulling back from an earlier session high, with a "Sell" rating and a price target of $191.

22 wrz 2026, 20:07 UTC

AbbVie received European Commission approval for RINVOQ to treat active polyarticular juvenile idiopathic arthritis, leading to a modest increase in shares.

21 wrz 2026, 20:06 UTC

AbbVie Inc. is collaborating with Iambic Therapeutics on small molecule therapies, while also acquiring a stake in ADARx Pharmaceuticals, driving shares higher.

18 wrz 2026, 23:06 UTC

AbbVie Inc. is experiencing a slight decline in after-market trading, positioned near the lower end of its recent trading range despite promising myeloma study results.

16 wrz 2026, 19:26 UTC

AbbVie shares moved lower as traders monitor the stock's approach to a 52-week high, with $267.47 seen as a critical resistance level.

15 wrz 2026, 23:01 UTC

AbbVie Inc. shares fell in after-hours trading, reflecting broader market negativity following a decline in the New York Empire State Manufacturing Index.

14 wrz 2026, 21:56 UTC

Shares of AbbVie Inc. are trading higher in after-market hours, maintaining a position above the 20-day moving average and reflecting recent upward trends.

11 wrz 2026, 20:08 UTC

AbbVie Inc. shares are higher following positive Phase 3 LUNA study results for atogepant and strong response rates for investigational BCMA×CD3 BiTE in multiple myeloma trials.

10 wrz 2026, 23:41 UTC

AbbVie Inc declared a quarterly dividend of $1.73, with a record date of October 15, 2026. Shares are higher in after-hours trading.

9 wrz 2026, 23:01 UTC

AbbVie Inc. shares advanced in after-market trading, recovering from earlier lows amid broader market dynamics and rising inflation concerns linked to geopolitical tensions.

8 wrz 2026, 23:06 UTC

AbbVie Inc. shares are higher in after-market hours, following a pullback earlier in the session amid broader market expectations for a Federal Reserve rate hike.

4 wrz 2026, 23:05 UTC

AbbVie Inc. shares are lower in after-market hours, reflecting cautious market sentiment amid mixed economic signals and a slight uptick in the unemployment rate.

3 wrz 2026, 23:11 UTC

AbbVie Inc. shares are trading higher in after-market hours following positive results from the Phase 3 CERVINO study of etentamig for multiple myeloma.

2 wrz 2026, 23:51 UTC

AbbVie Inc. shares are lower in after-market trading, despite remaining above the 20-day moving average, amid a weaker-than-expected ADP payrolls report.

1 wrz 2026, 23:56 UTC

AbbVie Inc. has filed for a new Skyrizi regimen to treat Crohn's disease. Shares are lower in after-market hours amid broader market pressure from rising oil prices.

31 sie 2026, 23:01 UTC

AbbVie Inc shares are higher in after-market trading, reflecting positive momentum. No specific company news was identified to explain the price movement.

28 sie 2026, 20:08 UTC

AbbVie shares are lower as the company seeks European approval for SKYRIZI. Rising U.S. Treasury yields amid inflation concerns contribute to market declines.

27 sie 2026, 23:01 UTC

AbbVie Inc. seeks European approval for SKYRIZI to treat Crohn's disease. Shares are higher in after-hours trading following a recent dip.

26 sie 2026, 23:02 UTC

AbbVie Inc shares are trading lower in after-market hours, showing volatility after Wednesday's close with no specific news identified to explain the movement.

25 sie 2026, 20:07 UTC

AbbVie Inc shares are higher, supported by favorable macro conditions and lower Treasury yields. The stock is trading near the upper end of its one-month range.

24 sie 2026, 19:36 UTC

AbbVie Inc. shares are trading lower today, having reached a session low earlier. The stock remains above its 20-day moving average.

21 sie 2026, 20:06 UTC

AbbVie Inc is set to present new data on its bispecific antibody at the 2026 World Conference on Lung Cancer, boosting investor sentiment. Shares are higher today.

20 sie 2026, 19:31 UTC

AbbVie shares are lower today, despite Piper Sandler raising its price target to $303 from $298. The decline aligns with broader sector weakness.

19 sie 2026, 23:01 UTC

AbbVie Inc. is lower in after-market trading, driven by declines in the Biotechnology sub-sector. Recent sessions had shown upward momentum.

18 sie 2026, 23:51 UTC

Abbvie Inc shares are trading higher in after-market hours, reflecting resilience amid elevated bond yields and inflation concerns. The stock remains above its 20-day moving average.

17 sie 2026, 23:51 UTC

AbbVie Inc shares are trading lower in after-market hours amid weak broader market sentiment influenced by geopolitical tensions and rising crude oil prices.

14 sie 2026, 19:46 UTC

AbbVie Inc has begun a Phase 2 trial for ABBV-295, yet shares are lower amid negative market sentiment from a decline in U.S. retail sales.